Fol. Biol. 2012, 58, 231-237

https://doi.org/10.14712/fb2012058060231

Paraoxonase-1 (PON1) Status in Pancreatic Cancer: Relation to Clinical Parameters

Marek Vecka1, M. Jáchymová2, L. Vávrová1, J. Kodydková1, J. Macášek1, M. Urbánek1, T. Krechler1, A. Slabý1, J. Dušková3, A. Muravská2, A. Žák1

14th Department of Internal Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic
2Institute for Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic
3Institute of Pathology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic

Received June 2012
Accepted June 2012

References

1. Ahotupa, M., Ruutu, M., Mäntylä, E. (1996) Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin. Biochem. 29, 139-144. <https://doi.org/10.1016/0009-9120(95)02043-8>
2. Akcay, M. N., Polat, M. F., Yilmaz, I., Akcay, G. (2003) Serum paraoxonase levels in pancreatic cancer. HepatoGastroenterology 50, Suppl II, ccxxv-ccxxvii.
3. Alberti, K. G., Zimmet, P. Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet. Med. 15, 539-553. <https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S>
4. Arioz, D. T., Camuzcuoglu, H., Toy, H., Kurt, S., Celik, H., Erel, O. (2009) Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer. Eur. J. Gynaecol. Oncol. 30, 679-682.
5. Bhattacharyya, T., Nicholls, S. J., Topol, E. J., Zhang, R., Yang, X., Schmidt, D., Fu, X., Shao, M., Brennan, D. M., Ellis, S. G., Brennan, M. L., Allayee, H., Lusis, A. J., Hazen, S. L. (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299, 1265-1276. <https://doi.org/10.1001/jama.299.11.1265>
6. Deakin, S., Leviev, I., Nicaud, V., Gustini, P., Grison, E., Pizzolo, F., Friso, S., Trabetti, E., Pignatti, P.F., Corrocher, R., Olivieri, O., Girelli, D. (2002) Paraoxonase-1 L55M polymorphism is associated with abnormal oral glucose tolerance test and differentiates high risk coronary disease families. J. Clin. Endocrin. Metab. 87, 1268-1273. <https://doi.org/10.1210/jcem.87.3.8335>
7. Deakin, S. P., James, R. W. (2004) Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. (Lond.) 107, 435-447. <https://doi.org/10.1042/CS20040187>
8. Draganov, D. I., Stetson, P. L., Watson, C. E., Billecke, S. S., La Du, B. N. (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 275, 33435-33442. <https://doi.org/10.1074/jbc.M004543200>
9. Ece, A., Gürkan, F., Celik, F., Boşnak, M., Yel, S., Balik, H., Erel, O. (2007) Paraoxonase, total antioxidant activity and peroxide levels in marasmic children: relationships with leptin. Clin. Biochem. 40, 634-639. <https://doi.org/10.1016/j.clinbiochem.2007.03.001>
10. Fang, D. H., Fan, C. H., Ji, Q., Qi, B. X., Li, J, Wang, L. (2012) Different effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol. Biol. Rep. 39, 6801-6809. <https://doi.org/10.1007/s11033-012-1505-3>
11. Ferlay, J., Parkin, D. M., Steliarova-Foucher, E. (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer. 46, 745-781. <https://doi.org/10.1016/j.ejca.2009.12.014>
12. Flekač, M., Škrha, J., Zídková, K., Lacinová, Z., Hilgertová, J. (2008) Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol. Res. 57, 717-726. <https://doi.org/10.33549/physiolres.931285>
13. Fleming, I. D., Cooper, J. S., Henson, D. E., Hutter, R. V. P., Kennedy, B. J., Murphy, G. P., O’Sullivan, B., Sobin, L. H., Yarbro, J. W. (eds.) (1997) AJCC. Cancer Staging Manual. 5th ed. Philadelphia-New York, Lippincott-Raven.
14. Goswami, B., Tayal, D., Gupta, N., Mallika, V. (2009) Paraoxonase: a multifaceted biomolecule. Clin. Chim. Acta 410, 1-12. <https://doi.org/10.1016/j.cca.2009.09.025>
15. Hassan, M. M., Bondy, M. L., Wolff, R. A., Abbruzzese, J. L., Vauthey, J. N., Postere, P. W., Evans, D. B., Khan, R., Chou, T. H., Lenzi, R., Jiao, L., Li, D. (2007) Risk factors for pancreatic cancer: case-control study. Am. J. Gastroenterol. 102, 2696-2707. <https://doi.org/10.1111/j.1572-0241.2007.01510.x>
16. Hendrick, C. C., Thorpe, S. R., Fu, M. X., Harper, C. M., Yoo, J., Kim, S. M., Wong, H., Peters, A. L. (2000) Glycation impairs high-density lipoprotein function. Diabetologia 43, 312-320. <https://doi.org/10.1007/s001250050049>
17. Hussein, Y. M., Gharib, A. F., Etewa, R. L., ElSawy, W. H. (2011) Association of L55M a Q192 polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol. Cell. Biochem. 351, 117-123. <https://doi.org/10.1007/s11010-011-0718-4>
18. Institute of Health Information and Statistics of the Czech Republic (IHIS) and Council of the National Oncological Registry of the Czech Republic (NOR) (2011) Cancer Incidence 2008. ÚZIS and NOR ČR. Prague.
19. James, R. W. (2006) A long and winding road: defining the biological role and clinical importance of paraoxonase. Clin. Chem. Lab. Med. 44, 1052-1059. <https://doi.org/10.1515/CCLM.2006.207>
20. Karaman, E., Uzun, H., Papila, I., Balci, H., Ozdilek, A., Genc, H., Yanardag, H., Papila, C. (2010) Serum paraoxonase activity and oxidative DNA damage in patients with laryngeal squamous cell carcinoma. J. Craniofac. Surg. 21, 1745-1749. <https://doi.org/10.1097/SCS.0b013e3181f4040a>
21. Kodydková, J., Vávrová, L., Zeman, M., Jirák, R., Macášek, J., Staňková, B., Tvrzická, E., Žák, A. (2009) Antioxidative enzymes and increased oxidative stress in depressive women. Clin. Biochem. 42, 1368-1374. <https://doi.org/10.1016/j.clinbiochem.2009.06.006>
22. Krechler, T., Zeman, M., Vecka, M., Macášek, J., Jáchymová, M., Zima, T., Žák, A. (2011) Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma 58, 58-64. <https://doi.org/10.4149/neo_2011_01_58>
23. Lee, C. H., Lee, K. Y., Choe, K. H., Hong, Y. C., Kim, Y. D., Kang, J. W., Kim, H. (2005) Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of paraoxonase-1 (PON-1) gene on lung cancer. J. Prev. Med. Publ. Health 38, 345-350.
24. Lenk, K., Schuler, G., Adams, V. (2010) Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Chachexia Sarcopenia Muscle 1, 9-21. <https://doi.org/10.1007/s13539-010-0007-1>
25. Leviev, I., James, R. W. (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20, 516-521. <https://doi.org/10.1161/01.ATV.20.2.516>
26. Mackness, B., Mackness, M. I., Arron, S., Turkie, W., Durrington, P. N. (1997) Effect of molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122, 265-268. <https://doi.org/10.1038/sj.bjp.0701390>
27. Maritim, A. C., Sanders, R. A., Watkins, J. B. (2003) Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17, 24-38. <https://doi.org/10.1002/jbt.10058>
28. McMillan, D. C. (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 12, 223-226. <https://doi.org/10.1097/MCO.0b013e32832a7902>
29. Miller, S. A., Dykes, D. D., Polesky, H. F. (1988) A simple salting out extraction DNA from human nucleated cells. Nucleic Acids Res. 16, 1215. <https://doi.org/10.1093/nar/16.3.1215>
30. Pannala, R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., Chari, S. T. (2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134, 981-987. <https://doi.org/10.1053/j.gastro.2008.01.039>
31. Précourt, L. P., Amre, D., Denis, M. C., Lavore, J. C., Delvin, E., Seidman, E., Levy, E. (2011) The three-gene paraoxonase family: physiologic roles, action and regulation. Atherosclerosis 214, 20-36. <https://doi.org/10.1016/j.atherosclerosis.2010.08.076>
32. Samra, Z. Q., Pervaiz, S., Shaheen, S., Dar, N., Athar, M. A. (2011) Determination of oxygen derived free radicals producer (xanthine oxidase) and scavenger (paraoxonase 1) enzymes and lipid parameters in different cancer patients. Clin. Lab. 57, 741-747.
33. Silvério, R., Lavino, A., Rossi Fanelli, F., Seelaender, M. (2011) L-carnitine and cancer cachexia: clinical and experimental aspects. J. Cachexia Sarcopenia Muscle 2, 3744. <https://doi.org/10.1007/s13539-011-0017-7>
34. Soran, H., Younis, N. N., Charlton-Menys, V., Durrington, P. (2009) Variation in paraoxonase-1 activity and atherosclerosis. Curr. Opin. Lipidol. 20, 265-274. <https://doi.org/10.1097/MOL.0b013e32832ec141>
35. Tavori, H., Aviram, M., Khatib, S., Musa, R., Mannheim, D., Karmeli, R., Vaya, J. (2011) Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284. Free Radic. Biol. Med. 50, 148-156. <https://doi.org/10.1016/j.freeradbiomed.2010.10.708>
36. Valko, M., Rhodes, C. J., Moncol, J., Izakovic, M., Mazur, M. (2006) Free radicals, metals, and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 160, 1-40. <https://doi.org/10.1016/j.cbi.2005.12.009>
37. Van den Berg, S. W., Jansen, E. H., Kruijshoop, M., Beekhof, P. K., Blaak, E., van der Kallen, C. J., van Greevenbroek, M. M., Feskens, E. J. (2008) Paraoxonase 1 phenotype distribution and activity differ in subjects with newly diagnosed Type 2 diabetes (the CODAM Study). Diabet. Med. 25, 186-193. <https://doi.org/10.1111/j.1464-5491.2007.02328.x>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Archive